Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Thermo Fisher Scientific touts new mass spectrometers

By Chris Newmarker | May 27, 2020

Thermo Fischer ScientificThermo Fisher Scientific has added two mass spectrometers — the Thermo Scientific Orbitrap Exploris 240 and Thermo Scientific Orbitrap Exploris 120 — to its Thermo Scientific Orbitrap Exploris portfolio.

The Thermo Scientific Orbitrap Exploris 240 mass spectrometer boasts the latest generation of system architecture and instrument control software to boost data acquisition and analysis capabilities for small- and large-molecule applications. The system includes positive/negative mode switching for comprehensive sample coverage, fast scan speeds and functionalities including Thermo Scientific AcquireX intelligent data acquisition workflow for greater automation.

“Scientists are seeking technologies that can streamline and speed proteomics studies to clinical applications, reduce time to market for candidate biotherapeutics and address the growing challenge of characterizing novel chemical entities in small-molecule studies,” said Iain Mylchreest, VP of research and development for analytical instruments at Thermo Fisher Scientific.

“As part of our expanded portfolio of new-generation instruments, the Orbitrap Exploris 240 mass spectrometer delivers the high performance and versatility needed to drive productivity across multiple applications,” Mylchreest said in a news release yesterday.

The Thermo Scientific Orbitrap Exploris 120 mass spectrometer meanwhile has fast scanning modes and rapid polarity switching that result in comprehensive sample coverage and increased productivity, according to Thermo Fisher Scientific. It delivers benefits for high-throughput screening and quantitation assays, according to the company

“Scientists running small molecule studies and applications in areas such as metabolomics, environmental analysis, metabolite identification, forensic toxicology, and anti-doping, require complete sample coverage in their analyses, without compromising productivity,” said August Specht, VP of research and development for chromatography and mass spectrometry at Thermo Fisher Scientific.

“The Orbitrap Exploris 120 mass spectrometer was designed specifically for laboratories to safeguard their current assays and enhance their provision of high-throughput and differentiated services, while simultaneously minimizing required training and method development times,” Specht said.

Thermo Fischer is showcasing the new systems at its virtual event, vLC-MS, being held May 26–28, 2020, and the American Society for Mass Spectrometry (ASMS) Reboot Program scheduled June 1–12, 2020.

Other announcements related to the virtual event include next-generation analytical software to strengthen data exploration, a collaboration with MSAID to provide access to deep learning tools for discovery and targeted proteomics, and an extended collaboration with Biognosys to enhance protein quantitation mass spectrometry workflows.


Filed Under: Drug Discovery and Development
Tagged With: Thermo Fisher Scientific
 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE